[
  {
    "ts": "2026-01-24T12:11:22+00:00",
    "headline": "How Investors May Respond To Bio-Techne (TECH) Doubling Down On Multi-Omic Integration Under New Leadership",
    "summary": "Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, emphasizing automated diagnostic platforms and multi-omic integration, while also scheduling a February 4, 2026 conference call to review second-quarter fiscal 2026 results. An interesting angle is management’s emphasis on operational integration and cross-selling across spatial biology, proteomics, and cell and gene therapy tools, supported by a balance sheet...",
    "url": "https://finance.yahoo.com/news/investors-may-respond-bio-techne-121122987.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "fd7f2994-c571-3175-8e9b-6b85e51d01bb",
      "content": {
        "id": "fd7f2994-c571-3175-8e9b-6b85e51d01bb",
        "contentType": "STORY",
        "title": "How Investors May Respond To Bio-Techne (TECH) Doubling Down On Multi-Omic Integration Under New Leadership",
        "description": "",
        "summary": "Earlier in 2026, Bio-Techne highlighted its leadership in spatial biology and proteomic analysis under new CEO Kim Kelderman, emphasizing automated diagnostic platforms and multi-omic integration, while also scheduling a February 4, 2026 conference call to review second-quarter fiscal 2026 results. An interesting angle is management’s emphasis on operational integration and cross-selling across spatial biology, proteomics, and cell and gene therapy tools, supported by a balance sheet...",
        "pubDate": "2026-01-24T12:11:22Z",
        "displayTime": "2026-01-24T12:11:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0Ih9Jyeb4E8RAOq22ZtFHA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r5jgPUxQrxmcesBmGBKgkQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-bio-techne-121122987.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-bio-techne-121122987.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TECH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]